{"id":109314,"date":"2026-03-03T11:47:15","date_gmt":"2026-03-03T10:47:15","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/a-team-at-irb-barcelona-uncovers-the-mechanism-of-a-pioneering-drug-designed-to-target-previously-undruggable-proteins\/"},"modified":"2026-03-03T12:45:41","modified_gmt":"2026-03-03T11:45:41","slug":"a-team-at-irb-barcelona-uncovers-the-mechanism-of-a-pioneering-drug-designed-to-target-previously-undruggable-proteins","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/a-team-at-irb-barcelona-uncovers-the-mechanism-of-a-pioneering-drug-designed-to-target-previously-undruggable-proteins\/","title":{"rendered":"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins"},"content":{"rendered":"

Scientists at the Institute for Research in Biomedicine in Barcelona (IRB Barcelona<\/a>), headquartered at the Barcelona Science Park, have uncovered the mechanism by which an experimental drug is able to block intrinsically disordered proteins, which had long been considered \u201cundruggable.\u201d The study, published in Science Advances<\/em>, shows that the drug does not act on the isolated protein; instead, it takes advantage of the moment when these proteins transiently cluster into small complexes known as oligomers. This discovery forms the scientific foundation of IRB Barcelona\u2019s spin-off, Nuage Therapeutics<\/a>, and paves the way for the design and optimization of new therapies against cancer and other diseases associated with this type of protein.<\/strong><\/p>\n

Intrinsically disordered proteins lack a fixed structure, which is why they have been considered “undruggable” targets for drug development for years. However, these proteins play a key role in numerous diseases\u2014ranging from various types of cancer to neurodegenerative disorders\u2014long limiting the therapeutic options available to treat them.<\/p>\n

Now, a team from IRB Barcelona led by Dr. Xavier Salvatella<\/strong> has successfully explained how a drug is able to bind to one of these disordered proteins, revealing a mechanism that opens new avenues for therapeutic design. The study, published in the journal Science Advances<\/em>, shows that the key lies not in the protein in isolation, but in a transient state that occurs when multiple copies of the protein begin to cluster.<\/p>\n

\u201cFor a long time, these proteins were thought to be impossible to target because they lack a stable structure. Our study demonstrates that, at certain moments, they adopt more organized conformations, and these windows of opportunity can be exploited to develop new treatments,\u201d explains Dr. Xavier Salvatella<\/strong>, ICREA researcher and head of the Molecular Biophysics Laboratory at IRB Barcelona.<\/p>\n

A moving target, but not an impossible one<\/strong><\/h3>\n

Intrinsically disordered proteins play a key role in many cellular processes, but because they lack a rigid, well-defined structure, they have been considered impossible targets for drug development for years. This new study demonstrates that this view was incomplete: when these proteins begin to cluster, they form transient oligomers in which certain structural elements appear. It is in this intermediate state that the drug can recognize its target and bind to it selectively, as the team has shown using biophysical techniques and cellular experiments.<\/p>\n

Understanding the mechanism to design better drugs<\/strong><\/h3>\n

\u201cUnderstanding the mechanism is a key step; it allows us to optimize these molecules and design new ones that take advantage of these transient states in disordered proteins,\u201d adds Dr. Stas\u0117 Bielskut\u0117-Garc\u00eda<\/strong>, the first author of the study.<\/p>\n

This knowledge not only explains why this compound works, but also provides a rational basis for designing new drugs targeting these types of proteins\u2014opening the door to new therapeutic strategies for diseases that currently have limited treatment options.<\/p>\n

The scientific foundation of Nuage Therapeutics<\/strong><\/h3>\n

The mechanism described in this study provides the scientific foundation for the IRB Barcelona spin-off Nuage Therapeutics, which was created to develop drugs targeting intrinsically disordered proteins\u2014a class of therapeutic targets traditionally considered inaccessible.<\/p>\n

The company applies this knowledge to identify and optimize molecules capable of recognizing the transient structural states of these proteins, following the exact strategy now detailed in the publication. Currently, Nuage Therapeutics focuses its efforts on small-cell lung cancer and various gastrointestinal cancers\u2014two areas with significant unmet medical needs where these types of proteins play a key role.<\/p>\n

Beyond oncology, Nuage Therapeutic\u2019s ultimate goal is to become the leader in the field of intrinsically disordered proteins, expanding the use of this technology into therapeutic areas where protein disorder plays a key role and treatment options remain limited.<\/p>\n

\u00bb Article of reference: <\/strong>Oligomerization enables the selective targeting of an intrinsically disordered region by a small molecule. Stas\u0117 Bielskut\u0117-Garc\u00eda, Borja Mateos, Muhammad Awawdy, Carla Garcia-Cabau, Henri Niskanen, Carolina S\u00e1nchez-Zarzalejo, Lorenzo Bracaglia, Roberta Pierattelli, Isabella C. Felli, Marta Frigol\u00e9-Vivas, Jes\u00fas Garc\u00eda, Antoni Riera, Denes Hnisz, Xavier Salvatella. Science Advances (2026)\u00a0DOI: 10.1126\/sciadv.adz74<\/a><\/p>\n

\u00bb Access to the news: <\/strong>IRB website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Scientists at the Institute for Research in Biomedicine in Barcelona (IRB Barcelona), headquartered at the Barcelona Science Park, have uncovered the mechanism by which an experimental drug is able to…<\/p>\n","protected":false},"author":14,"featured_media":109323,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[36],"tags":[260],"class_list":["post-109314","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-irb-en"],"acf":[],"yoast_head":"\nA team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"This discovery forms the scientific foundation of Nuage Therapeutics and paves the way for the design and optimization of new cancer therapies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"This discovery forms the scientific foundation of Nuage Therapeutics and paves the way for the design and optimization of new cancer therapies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T10:47:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T11:45:41+00:00\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins\",\"datePublished\":\"2026-03-03T10:47:15+00:00\",\"dateModified\":\"2026-03-03T11:45:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/\"},\"wordCount\":690,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fotos-web-900x330-px-16.png\",\"keywords\":[\"IRB\"],\"articleSection\":[\"SCIENCE\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/\",\"name\":\"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fotos-web-900x330-px-16.png\",\"datePublished\":\"2026-03-03T10:47:15+00:00\",\"dateModified\":\"2026-03-03T11:45:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"This discovery forms the scientific foundation of Nuage Therapeutics and paves the way for the design and optimization of new cancer therapies\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fotos-web-900x330-px-16.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fotos-web-900x330-px-16.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins - Parc Cient\u00edfic de Barcelona","description":"This discovery forms the scientific foundation of Nuage Therapeutics and paves the way for the design and optimization of new cancer therapies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/","og_locale":"en_US","og_type":"article","og_title":"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins - Parc Cient\u00edfic de Barcelona","og_description":"This discovery forms the scientific foundation of Nuage Therapeutics and paves the way for the design and optimization of new cancer therapies","og_url":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-03-03T10:47:15+00:00","article_modified_time":"2026-03-03T11:45:41+00:00","author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins","datePublished":"2026-03-03T10:47:15+00:00","dateModified":"2026-03-03T11:45:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/"},"wordCount":690,"image":{"@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/03\/fotos-web-900x330-px-16.png","keywords":["IRB"],"articleSection":["SCIENCE"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/","url":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/","name":"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/03\/fotos-web-900x330-px-16.png","datePublished":"2026-03-03T10:47:15+00:00","dateModified":"2026-03-03T11:45:41+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"This discovery forms the scientific foundation of Nuage Therapeutics and paves the way for the design and optimization of new cancer therapies","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/03\/fotos-web-900x330-px-16.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/03\/fotos-web-900x330-px-16.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/un-equip-de-lirb-barcelona-revela-el-mecanisme-dun-farmac-pioner-per-atacar-proteines-inabordables\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"A team at IRB Barcelona uncovers the mechanism of a pioneering drug designed to target previously \u201cundruggable\u201d proteins"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/109314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=109314"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/109314\/revisions"}],"predecessor-version":[{"id":109318,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/109314\/revisions\/109318"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/109323"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=109314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=109314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=109314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}